Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...

A rumor regarding Legend Biotech (LEGN) was highlighted in an alert sent to subscribers of Ben Harrington’s takeover-focused Betaville blog, contacts tell The Fly. Shares of Legend Biotech ...

Prime Minister Narendra Modi on Thursday released the genome sequencing data of 10,000 Indian nationals and said it will be a milestone in the field of biotechnology research. The Genome India ...

Under the terms of the agreement, Windward Bio is granted an exclusive license to research, develop, manufacture, and commercialize HBM9378/SKB378 globally, excluding Greater China and several ...

Tim Barat loved being a lineman at an electric company in Australia, where he grew up, even in the chaos of the Black Saturday brushfires in 2009 that torched over 1 million acres and left many ...

Established industrial systems have historically been designed to function as linear frameworks, transforming raw materials—including fossil and renewable resources—into products that become waste ...

Once you get over the ick factor, new technologies are efficiently transforming human waste into agricultural solutions. A new industrial facility in suburban Seattle is giving off a whiff of ...

Re­gen­eron, mak­er of the block­buster oph­thal­mol­o­gy med­i­cine Eylea, has ac­quired an oc­u­lar biotech, the large bio­phar­ma con­firmed to End­points News on Thurs­day.

The Currys January sale is still chugging along right now with savings of up to 40% off available on over 1000 products. Of course, not everything is a bargain and some of the strongest offers ...

Regeneron has scooped up Oxular, a retinal-disease-focused company based in the U.K., closing the deal at the very end of 2024. Word of the acquisition was first shared by Oxular’s former CEO ...

From Air Force One to armored cars like "the Beast," the president of the United States tends to travel with a degree of style and fanfare. Until the 1970s, perhaps the ultimate option was the US ...

The biotechnology sector once again starts a new year on shaky footing. Acquisitions of publicly traded biotech companies have slowed. An anticipated upswing in initial public offerings hasn’t ...